

Advancing NIH Research on the Health of Women: A 2021 Conference

A path forward towards accelerating cervical cancer eradication

Diana SM Buist, PhD, MPH Senior Scientific Investigator, Kaiser Permanente Washington Health Research Institute Professor, Kaiser Permanente Bernard J. Tyson School of Medicine

Affiliate Professor, University of Washington, School of Public Health, Departments of Epidemiology and Health Systems and Population Health




Facebook: /NIHORWH Twitter: @NIH_ORWH www.nih.gov/women #ResearchForWomen

Disclosures

- Funded by: NCI, AHRQ, PCORI and CDC
 - Co-I on Completed NCI trial: Home-Based Options to Make Cervical Cancer Screening Easy (HOME) trial NCT02005510 (R01 CA168598) Clinical outcomes in underscreened females
 - PI on NCI trial Self-Testing Options in the Era of Primary HPV Screening for Cervical Cancer Trial (STEP) NCT04679675 (R01 CA240375)

Screening uptake and completion by different outreach strategies stratified by screening history

• Employed by Kaiser Foundation Health Plan of Washington



90%

Global strategy to accelerate the elimination of cervical cancer as a public health problem



Achieving the 90-70-90 targets by 2030 would result in over 62 million cervical cancer deaths averted by 2120.

of women are screened with a high-performance test by 35 years of age and again by 45 years of age.


70%

of women identified with cervical disease receive treatment (90% of women with precancer treated, and 90% of women with invasive cancer managed).

90%

World Heat Organizat





Cancer Prevention through Vaccination with Long Sojourn time

5


US population of females aged 30-64


73,180,000 18,295,000 14,000

50%

bodyimage childcare inconvenience Knowledge transportation e ural Work 3/1.

Percent up-to-date with cervical cancer screening by insurance status in the US















	Mailed HPV Kit	Usual Care	RR (95% CI)
Screening initiation	2646 (26.6%)	1917 (17.4%)	1.53 (1.45-1.61)
Screening completed	2618 (26.3%)	1917 (17.4%)	1.51 (1.43-1.60)

JAMA Netw Open 2019 NCT02005510 (R01 CA168598)



In-Home

Colposcopyneeded


In-clinic testing


Home test negative, screening complete


Instructions for Your Cervical Cancer Screening Kit

kaiser Permanente.


Please do not use this kit if you are pregnant.







D



JAMA Netw Open 2019 NCT02005510 (R01 CA168598) NCT04679675 (R01 CA240375)

STEP 1

STEP 2

STEP 3


STEP 4

JOURNAL OF WOMEN'S HEALTH Volume 00, Number 00, 2018 © Mary Ann Liebert, Inc. DOI: 10.1089/jwh.2018.7070

Understanding Patients' Perspectives and Information Needs Following a Positive Home Human Papillomavirus Self-Sampling Kit Result

Jasmin A. Tiro, PhD,¹ Andrea C. Betts, MPH,^{1,2} Kilian Kimbel, BA,³ Diana S.M. Buist, PhD,³ Constance Mao, MD,⁴ Hongyuan Gao, MS,³ Lisa Shulman, MSW,³ Colin Malone, MPH,⁵ Tara Beatty, MA,³ John Lin, BA,⁶ Chris Thayer, MD,⁷ Diana L. Miglioretti, PhD,^{3,8} and Rachel L. Winer, PhD^{3,5}

> Reactions of women underscreened for cervical cancer who received unsolicited human papillomavirus self-sampling kits






J Med Screen 2020, Vol. 27(3) 146–156 © The Author(s) 2019 Article reuse guidelines: sagepub.com/journals-permissions DOI: 10.1177/0969141319885994 journals.sagepub.com/home/msc

> NCT02005510 R01 CA168598

Self-Testing options in the Era of Primary HPV screening for cervical cancer STEP Trial



31,619 females ages 30-64 due for cervical cancer screening recruited over 14 months

NCT04679675 (R01 CA240375) Clinical Trial: NCT04679675 (Buist/Winer)



Open Access Full Text Article

REVIEW

Cervical Cancer Screening Postpandemic: Self-Sampling Opportunities to Accelerate the Elimination of Cervical Cancer


Taja Lozar¹⁻³ Rahul Nagvekar⁴ Charles Rohrer D⁵ Racheal Shamiso Dube Mandishora^{6,7} Urska Ivanus D^{3,8,9} Megan Burke Fitzpatrick D^{1,5}


O Comment on this paper

Relative Sensitivity of ID NOW and RT-PCR for Detection of

SARS-CoV-2 in an Ambulatory Population: Clinical Evaluation, Systematic Review and Meta-analysis


Yuan-Po Tu, Jameel Iqbal, D Timothy O'Leary doi: https://doi.org/10.1101/2020.12.07.20245225 Now published in *eLife* doi: 10.7554/eLife.65726





Individual patient

Biological factors Socio-demographics Insurance coverage Risk status Comorbidities Knowledge, attitudes, beliefs Decision-making preferences Psychological reaction/coping



Recommendations

- Learn from COVID
 - Primary prevention & education: What has worked to address vaccine hesitancy, how have complex scientific concepts been relayed to the public
 - ✓ Self-collection: increase validation and implementation evaluations
 ✓ Speed
- Multi-everything
 - ✓ Multi-level, multi-site, multi-modalities (mixed methods), multi-lingual & multi-cultural
- Invest in training for researchers to communicate to various stakeholders
- Reform NIH funding paradigm

✓ Faster

✓ Innovative funding mechanisms (e.g., UG3-UH3; NIDDK PAR-20-160)

